In recent years, the English concept of “early treatment” (ET) has become widespread in the scientific literature as a fundamental part of secondary prevention. This involves preventing the progression and complications of a disease once it has been diagnosed. Early treatment involves therapeutic intervention as soon as a pathology is diagnosed and therefore implies early diagnosis to establish the most appropriate treatment for each patient based on the criteria of activity, severity or dimension of the disease.

BioSim has detected the need to promote a debate between different specialties and disciplines to address how the introduction of biosimilar medicines can promote that, in certain cases, TE strategies with biological medicines can be chosen, provided that the evidence shows a clinical benefit to patients.